糖化ヘモグロビン検査市場：タイプ、手法、エンドユーザー別-2025-2030年の世界予測

糖化ヘモグロビン検査市場は、2023年に6億8,636万USDと評価され、2024年には7億5,413万USDに達すると予測され、CAGR 9.96%で成長し、2030年には13億3,483万USDに達すると予測されています。

糖化ヘモグロビン検査は、HbA1c検査と呼ばれることが多く、通常2～3ヶ月間の平均血糖値を測定することにより、糖尿病管理において極めて重要な役割を果たしています。この検査は、糖尿病の診断とモニタリング、治療方針の決定、合併症のリスク軽減のために極めて重要です。その必要性は、糖尿病と糖尿病予備軍の世界の有病率の増加によって強調されており、その結果、病院や診断ラボだけでなく、在宅ケア環境での応用も拡大しています。最終用途には、糖尿病患者、ヘルスケアプロバイダー、さらには先進的な糖尿病管理戦略を模索する研究機関も含まれます。成長に影響を与える主な要因としては、ヘルスケア支出の増加、検査方法の技術的進歩、糖尿病ケアに関する消費者の意識の高まり、政府の支援政策などが挙げられます。市場の発展に伴い、便利でタイムリーな診断に対する需要の高まりに対応したポイントオブケア検査機器の統合や遠隔医療ソリューションの成長から潜在的な機会が生まれます。こうした機会を捉えるために、企業はユーザーフレンドリーで費用対効果の高い検査ソリューションの開発に注力し、デジタルプラットフォームを活用して幅広いアウトリーチとデータ統合を行うべきです。しかし、規制上の制約、高度な検査技術に関連する高コスト、新興国地域の認識不足といった制約が、市場拡大の課題となっています。さらに、ポイント・オブ・ケア機器の精度に関する懸念は、市場の受容を妨げる可能性があります。したがって、技術革新は検査精度の向上、コスト削減、非侵襲的検査技術の開発に重点を置くべきです。市場は本質的にダイナミックであり、継続的な技術進歩と激しい競争を特徴とし、大手企業は技術革新と市場シェアの獲得に努めています。利害関係者は、消費者のニーズや規制の動向を常に把握することで、課題を克服し、成長の道を切り開くことができ、糖化ヘモグロビン検査市場で持続的な成功を収めることができます。

市場力学：急速に進化する糖化ヘモグロビン検査市場の主要市場インサイトを公開

糖化ヘモグロビン検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 糖尿病など様々な慢性疾患の世界の罹患率の増加
  • 老年人口の増加による疾病への脆弱性の増大
  • 患者のセルフケアソリューションの急速な普及
• 市場抑制要因
  • 糖化ヘモグロビン検査機器に関連する高コスト
• 市場機会
  • 迅速診断検査やPCOTなど、在宅ヘルスケア市場に対する需要の高まり
  • 早期診断と効率的な疾病管理のための継続的な研究開発活動
• 市場の課題
  • HbA1c検査の限界と代替品の利用可能性

ポーターの5つの力：糖化ヘモグロビン検査市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：糖化ヘモグロビン検査市場における外部からの影響の把握

外部マクロ環境要因は、糖化ヘモグロビン検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析糖化ヘモグロビン検査市場における競合情勢の把握

糖化ヘモグロビン検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス糖化ヘモグロビン検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、糖化ヘモグロビン検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨糖化ヘモグロビン検査市場における成功への道筋を描く

糖化ヘモグロビン検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 糖尿病などのさまざまな慢性疾患の発症が世界中で増加している
    • 高齢者人口の増加は病気に対する脆弱性の増大につながる
    • 患者のセルフケアソリューションが急速に普及
  • 抑制要因
    • 糖化ヘモグロビン検査機器に関連する高コスト
  • 機会
    • 迅速診断検査やPCOTなどの在宅ヘルスケア市場への新たな需要
    • 早期診断と効率的な疾病管理のための継続的な研究開発活動
  • 課題
    • HbA1c検査の限界と代替品の入手可能性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 糖化ヘモグロビン検査市場：タイプ別

• 実験室ベースのテスト
• ポイントオブケアテスト

第7章 糖化ヘモグロビン検査市場：技術別

• ボロネートアフィニティークロマトグラフィー
• 直接酵素アッセイ
• 高速液体クロマトグラフィー
• 免疫測定

第8章 糖化ヘモグロビン検査市場：エンドユーザー別

• 学術調査機関
• 診断センター
• 病院

第9章 南北アメリカの糖化ヘモグロビン検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の糖化ヘモグロビン検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの糖化ヘモグロビン検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• A. Menarini Diagnostics s.r.l
• Abbott Laboratories Inc.
• ARKRAY, Inc.
• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc.
• Daiichi Biotech Services Sdn. Bhd.
• Danaher Corporation
• DiaSys Diagnostic Systems GmbH
• Diazyme Laboratories, Inc.
• EKF Diagnostics Holdings plc
• F. Hoffmann-La Roche AG
• Sebia
• Siemens AG
• TaiDoc Technology Corporation
• Tosoh Corporation
• Trinity Biotech

LIST OF FIGURES

• FIGURE 1. GLYCATED HEMOGLOBIN TESTING MARKET RESEARCH PROCESS
• FIGURE 2. GLYCATED HEMOGLOBIN TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GLYCATED HEMOGLOBIN TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. GLYCATED HEMOGLOBIN TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GLYCATED HEMOGLOBIN TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GLYCATED HEMOGLOBIN TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY POINT-OF-CARE TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY BORONATE AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY DIRECT ENZYMATIC ASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM GLYCATED HEMOGLOBIN TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. GLYCATED HEMOGLOBIN TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. GLYCATED HEMOGLOBIN TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Glycated Hemoglobin Testing Market was valued at USD 686.36 million in 2023, expected to reach USD 754.13 million in 2024, and is projected to grow at a CAGR of 9.96%, to USD 1,334.83 million by 2030.

Glycated hemoglobin testing, often referred to as HbA1c testing, plays a pivotal role in diabetes management by measuring average blood glucose levels over a period, typically 2-3 months. This test is crucial for diagnosing and monitoring diabetes, guiding therapeutic decisions, and reducing the risk of complications. Its necessity is underscored by the increasing global prevalence of diabetes and prediabetes, thus expanding its application not only in hospitals and diagnostic labs but also in home-care settings. The end-use scope encompasses individuals with diabetes, healthcare providers, and even research institutions exploring advanced diabetes management strategies. Key influencing growth factors include rising healthcare expenditure, technological advancements in testing methods, increased consumer awareness regarding diabetic care, and supportive governmental policies. As the market evolves, potential opportunities arise from the integration of point-of-care testing devices and the growth of telemedicine solutions, which align with the increasing demand for convenient and timely diagnostics. To seize these opportunities, businesses should focus on developing user-friendly, cost-effective testing solutions and leverage digital platforms for wider outreach and data integration. However, limitations such as regulatory constraints, high costs associated with advanced testing technologies, and a lack of awareness in developing regions pose challenges to market expansion. Additionally, accuracy concerns with point-of-care devices can impede market acceptance. Innovation should therefore focus on enhancing test accuracy, reducing costs, and developing non-invasive testing techniques. The market is inherently dynamic, characterized by continuous technological progression and intense competition, with major players striving to innovate and capture market share. By staying attuned to consumer needs and regulatory developments, stakeholders can navigate challenges and leverage growth avenues for sustained success in the glycated hemoglobin testing market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glycated Hemoglobin Testing Market

The Glycated Hemoglobin Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of various chronic diseases such as diabetes globally
  • Rising geriatric population leads to higher vulnerability for diseases
  • Rapid adoption attributed to patient self-care solutions
• Market Restraints
  • High cost pertinent to glycated hemoglobin testing equipment
• Market Opportunities
  • Emerging demand for home healthcare market such as rapid diagnostic tests and PCOT
  • Ongoing R&D activities for early diagnosis and efficient disease management
• Market Challenges
  • Limitation of HbA1c tests and availability of substitutes

Porter's Five Forces: A Strategic Tool for Navigating the Glycated Hemoglobin Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glycated Hemoglobin Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glycated Hemoglobin Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glycated Hemoglobin Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glycated Hemoglobin Testing Market

A detailed market share analysis in the Glycated Hemoglobin Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glycated Hemoglobin Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glycated Hemoglobin Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glycated Hemoglobin Testing Market

A strategic analysis of the Glycated Hemoglobin Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glycated Hemoglobin Testing Market, highlighting leading vendors and their innovative profiles. These include A. Menarini Diagnostics s.r.l, Abbott Laboratories Inc., ARKRAY, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Daiichi Biotech Services Sdn. Bhd., Danaher Corporation, DiaSys Diagnostic Systems GmbH, Diazyme Laboratories, Inc., EKF Diagnostics Holdings plc, F. Hoffmann-La Roche AG, Sebia, Siemens AG, TaiDoc Technology Corporation, Tosoh Corporation, and Trinity Biotech.

Market Segmentation & Coverage

This research report categorizes the Glycated Hemoglobin Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Laboratory Based Tests and Point-Of-Care Test.
• Based on Technique, market is studied across Boronate Affinity Chromatography, Direct Enzymatic Assay, High-Performance Liquid Chromatography, and Immunoassay.
• Based on End-User, market is studied across Academic & Research Institutes, Diagnostic Centers, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of various chronic diseases such as diabetes globally
    • 5.1.1.2. Rising geriatric population leads to higher vulnerability for diseases
    • 5.1.1.3. Rapid adoption attributed to patient self-care solutions
  • 5.1.2. Restraints
    • 5.1.2.1. High cost pertinent to glycated hemoglobin testing equipment
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging demand for home healthcare market such as rapid diagnostic tests and PCOT
    • 5.1.3.2. Ongoing R&D activities for early diagnosis and efficient disease management
  • 5.1.4. Challenges
    • 5.1.4.1. Limitation of HbA1c tests and availability of substitutes
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Glycated Hemoglobin Testing Market, by Type

• 6.1. Introduction
• 6.2. Laboratory Based Tests
• 6.3. Point-Of-Care Test

7. Glycated Hemoglobin Testing Market, by Technique

• 7.1. Introduction
• 7.2. Boronate Affinity Chromatography
• 7.3. Direct Enzymatic Assay
• 7.4. High-Performance Liquid Chromatography
• 7.5. Immunoassay

8. Glycated Hemoglobin Testing Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Diagnostic Centers
• 8.4. Hospitals

9. Americas Glycated Hemoglobin Testing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Glycated Hemoglobin Testing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Glycated Hemoglobin Testing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. A. Menarini Diagnostics s.r.l
• 2. Abbott Laboratories Inc.
• 3. ARKRAY, Inc.
• 4. Beckman Coulter, Inc.
• 5. Bio-Rad Laboratories, Inc.
• 6. Daiichi Biotech Services Sdn. Bhd.
• 7. Danaher Corporation
• 8. DiaSys Diagnostic Systems GmbH
• 9. Diazyme Laboratories, Inc.
• 10. EKF Diagnostics Holdings plc
• 11. F. Hoffmann-La Roche AG
• 12. Sebia
• 13. Siemens AG
• 14. TaiDoc Technology Corporation
• 15. Tosoh Corporation
• 16. Trinity Biotech